LIPIFIBRATE 105MG 30TAB

63.00 EGP

105 mg fenofibric acid

LIPIFIBRATE 105MG 30TAB; fenofibrate, cardiovascular agents .

ACTIVE-INGREDIENT OF LIPIFIBRATE 105MG 30TAB

105 mg fenofibric acid

INDICATION OF LIPIFIBRATE 105MG 30TAB

Severe hypertriglyceridemia : lipifibrate is indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia ( > 500 mg / dl) . Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides > 2000 mg/ dl may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Primary hypercholesterolemia or mixed dyslipidemia : lipifibrate is indicated as adjunctive therapy to diet to reduce elevated low – density lipoprotein cholesterol ( LDL-C ) , total cholesterol ( total – C) , triglycerides ( TG) , and apolipoprotein B ( apo B. ) , and to increase high – density lipoprotein cholesterol ( HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia. Important limitations of use : fenofibrate at a dose equivalent to 105 mg of lipifibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.

DOSAGE OF LIPIFIBRATE 105MG 30TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

General considerations : lipifibrate can be given without regard to meals. Patients should be advised to swallow lipifibrate tablets whole. Do not crush, dissolve or chew tablets . Patients should be placed on an appropriate lipid – lowering diet before receiving lipifibrate and should continue this diet during treatment with fenofibric acid. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure . Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta – blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglycerdemia . Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of lipifibrate. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 105 mg per day. Consideration should be given to reducing the dosage of lipifibrate if lipid levels fall significantly below the targeted range. Servere hypertriglyceridemia : the initial dose is 35 to 105 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 105 mg once daily. Primary hypercholesterolemia or mixed dyslipidemia : the dose of lipifibate is 105 mg per day. Impaired renal impairment, treatment with lipifibrate should be initiated at a dose of 35 mg once daily , and increased only after evaluation of the effects on renal function and lipid levels at this dose . The use of lipifirate should be avoided in patients with severe renal impairment . Geiatric patients : dose selection for the elderly should be made on the basis of renal function . ddosage forms and strengths : 105 – mg white oblong biconvex tablet .

OVER-DOSAGE OF LIPIFIBRATE 105MG 30TAB

there is no spesific treatment for overdose with lipifibrate . General supportive care of the patient is indicated , including monitoring of vital dsigns and observation of clinical status , should an overdose occur . If indicated , elimination of unabsorrbed drug should be achieved by emesis or gastric lavage , usual precautions should be observed to maintain the airway . because lipifibrate is highly bound to plasma proteins , hemodialysis should not be considered .

CONTRA-INDICATION OF LIPIFIBRATE 105MG 30TAB

lipifibrate is contraindicated in : patients with severe renal impairment , including those receiving dialysis . Patients with active liver disease , including those with primary biliary cirrhosis and unexplainedd persistent liver function abnormalities . patients with peexisting gallblader disease . patients with known hypersensitivity to fenofibric acid or fenofibrate . nursing mothers .

STORAGE OF LIPIFIBRATE 105MG 30TAB

Store at temperature not exceeding 30 C in a dry place .
PACK OF LIPIFIBRATE 105MG 30TAB
carton box containing 1 , 2 or 3 ( transparent PVC / AL ) blisters , each of 10 tablets + inner leaflet .
LIPIFIBRATE 105MG 30TAB MANUFACTURED BY
MASH PREMIEREE

https://www.webmd.com/drugs/2/drug-93290/fenofibrate-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “LIPIFIBRATE 105MG 30TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat